Sandbox sss: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 10: Line 10:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">; </font>High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">; </font>High:≥ 20 million units IV q24h(=12 g)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 g po IV q6h to max. of 4 g/day'''''
|-
|-
|}
|}
Line 37: Line 37:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 g IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cefotaxime]] or [[Ceftriaxone]] MIC† >1.0 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cefotaxime]] or [[Ceftriaxone]] MIC† >1.0 μg/mL}}
Line 59: Line 59:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''<sup>Ω<sup>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''<sup>Ω<sup>
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 84: Line 84:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">;</font>High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">;</font>High:≥ 20 million units IV q24h(=12 g)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''<BR><BR><BR>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 g po IV q6h to max. of 4 g/day'''''<BR><BR>
|-
|-
|}
|}
Line 111: Line 111:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 g IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 g po IV q6h to max. of 4 g/day'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 131: Line 131:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
|}
|}
Line 146: Line 146:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 g)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 163: Line 163:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 g)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 194: Line 194:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 g IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 g po IV q6h to max. of 4 g/day'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 226: Line 226:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 239: Line 239:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 g IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 g po IV q6h to max. of 4 g/day'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 275: Line 275:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1–2 gm IV/IM q4h
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1–2 g IV/IM q4h
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Oxacillin]] 1–2 gm IV/IM q4h
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Oxacillin]] 1–2 g IV/IM q4h
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 342: Line 342:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 364: Line 364:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 384: Line 384:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 g po q6h.150–200 mg/kg/day IV'''''
|-
|-
|}
|}
Line 398: Line 398:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime ]] 1–2 gm IV/IM q8–12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime ]] 1–2 g IV/IM q8–12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 g IV q12h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''

Revision as of 20:32, 16 January 2014

Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Streptococcus pneumoniae

Penicillin MIC ≤0.06 μg/mL
Preferred Regimen
Penicillin G Low: 600,000–1.2 million units/day IM ; High:≥ 20 million units IV q24h(=12 g)
OR
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol 0.25–1 g po IV q6h to max. of 4 g/day
Penicillin MIC ≥0.12 μg/mL
Cefotaxime or Ceftriaxone MIC† <1.0 μg/mL
Preferred Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 g IV q12h
OR
Meropenem 2 g IV q8h
Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)Ω
Alternative Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Moxifloxacin 400 mg po IV q24h ɸ

Neisseria meningitidis

Neisseria meningitidis
Penicillin MIC <0.1 μg/mL
Preferred Regimen
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 g)
OR
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol 0.25–1 g po IV q6h to max. of 4 g/day

Neisseria meningitidis
Penicillin MIC ≥0.1 μg/mL
Preferred Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 g IV q12h
OR
Chloramphenicol 0.25–1 g po IV q6h to max. of 4 g/day
OR
Fluoroquinolone
OR
Meropenem 2 g IV q8h

Listeria Monocytogenes and Streptococcus agalactiae

Listeria Monocytogenes
Preferred Regimen
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
OR
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 g)
Alternative Regimen
Trimethoprim-sulfamethoxazole 5–20 mg/kg/day q6-12h
Streptococcus agalactiae
Preferred Regimen
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
OR
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 g)
Alternative Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h

Haemophilus influenzae

Haemophilus influenzae
β-lactamase negative
Preferred Regimen (Adult)
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
Alternative Regimen (Adult)
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Cefepime 1–2 g IV q12h
OR
Chloramphenicol 0.25–1 g po IV q6h to max. of 4 g/day
OR
Aztreonam 1 g q8h–2 g IV q6h
OR
Fluoroquinolone
β-lactamase negative, ampicillin resistant
Preferred Regimen
Meropenem 2 g IV q8h
Alternative Regimen
Fluoroquinolone
Haemophilus influenzae
β-lactamase positive
Preferred Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 g IV q12h
OR
Chloramphenicol 0.25–1 g po IV q6h to max. of 4 g/day
OR
Aztreonam 1 g q8h–2 g IV q6h
OR
Fluoroquinolone

Staphylococcus aureus

Staphylococcus aureus
Meticillin sensitive
Preferred Regimen
Nafcillin 1–2 g IV/IM q4h
OR
Oxacillin 1–2 g IV/IM q4h
Alternative Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
OR
linezolid 600 mg IV/PO q12h
OR
Daptomycin
Staphylococcus aureus
Meticillin resistant
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
Alternative Regimen
Trimethoprim-sulfamethoxazole 5–20 mg/kg/day q6-12h
OR
linezolid 600 mg IV/PO q12h
OR
Daptomycin


Staphylococcus epidermidis and Acinetobacter baumannii

Staphylococcus epidermidis
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
Alternative Regimen
Linezolid 600 mg IV/PO q12h


Acinetobacter baumannii
Preferred Regimen
Meropenem 2 g IV q8h
Alternative Regimen
Colistin
OR
Polymyxin B 15,000–25,000 units/kg/day q12h

Enterobacteriaceae and Pseudomonas aeruginosa

Enterobacteriaceae
Preferred Regimen
Cefotaxime 1 g q8–12h to 2 g IV q4h
OR
Ceftriaxone 1 g IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Aztreonam 1 g q8h–2 g IV q6h
OR
Fluoroquinolone
OR
Trimethoprim-sulfamethoxazole
OR
Meropenem 2 g IV q8h
OR
Ampicillin 0.25–0.5 g po q6h.150–200 mg/kg/day IV
Pseudomonas aeruginosa
Preferred Regimen
Ceftazidime 1–2 g IV/IM q8–12h
OR
Cefepime 1–2 g IV q12h
Alternative Regimen
Aztreonam 1 g q8h–2 g IV q6h
OR
Meropenem 2 g IV q8h
OR
Ciprofloxacin 500-750 mg po bid